Lytix Biopharma (LYTIX) Q3 2025 earnings summary

Executive summary

• Ruxotemitide demonstrated strong Phase II results in basal cell carcinoma (51% complete histologic clearance, 97% objective response rate) and neoadjuvant melanoma (44% complete pathological response, 88% overall response), accelerating commercialization plans and supporting late-stage development.

• Strategic partnerships, notably with Verrica Pharmaceuticals, support regulatory alignment and late-stage development for BCC.

• LTX-401 is advancing toward clinical development, with positive preclinical data and regulatory feedback for deep-seated tumors.

• Focused on rapid commercialization through internal studies and partnerships, with expansion into both superficial and deep-seated tumor indications.

Financial highlights

• Q3 operating costs remained stable, with a one-off non-cash share option expense of NOK 11.9 million increasing reported net loss; underlying net loss for Q3 was NOK 11.5 million, consistent with previous quarters.

• Cash and short-term financial investments totaled NOK 90 million at quarter-end, providing a solid runway into 2026.

• Total liabilities declined to NOK 17 million, reflecting balance sheet normalization and reversal of ATLAS-IT-05 accrual.

• Direct R&D expenses for Q3 were NOK 4.8 million, in line with prior quarters and reflecting reduced clinical activity post-ATLAS-IT-05.

• Total equity at quarter-end was NOK 78.4 million.

Outlook and guidance

• Well-capitalized to fund operations and clinical milestones through 2026, with disciplined cost control and focus on value-driving milestones.

• Preparing for pivotal Phase III trials in BCC with FDA alignment and partnerships considered for financing.

• NeoLIPA topline results expected mid-2026, with last patient treatment anticipated mid-2026 and data presentation later that year.

• Open to partnerships to accelerate development and maximize global potential.